BIND files for IPO; Sophiris prepares for US trading
This article was originally published in Scrip
Executive Summary
Prolific partnership negotiator Bind Therapeutics registered an $80.5 million initial public offering to complete mid-stage trials for its only wholly-owned clinical asset and prepare for Phase III development.